|
1
|
Al-Sohaily S, Biankin A, Leong R,
Kohonen-Corish M and Warusavitarne J: Molecular pathways in
colorectal cancer. J Gastroenterol Hepatol. 27:1423–1431.
2012.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Ivanovich JL, Read TE, Ciske DJ, Kodner IJ
and Whelan AJ: A practical approach to familial and hereditary
colorectal cancer. Am J Med. 107:68–77. 1999.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Fearon ER and Vogelstein B: A genetic
model for colorectal tumourigenesis. Cell. 61:759–767.
1990.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Lengauer C, Kinzler KW and Vogelstein B:
Genetic instabilities in human cancers. Nature. 396:643–649.
1998.PubMed/NCBI View
Article : Google Scholar
|
|
6
|
Vogelstein B and Kinzler KW: Lessons from
hereditary colorectal cancer. Cell. 87:159–170. 1996.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Arrington A, Heinrich E, Lee W, Duldulao
M, Patel S, Sanchez J, Garcia-Aguilar J and Kim J: Prognostic and
predictive roles of KRAS mutation in colorectal cancer. Int J Mol
Sci. 13:12153–12168. 2012.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Baines AT, Xu D and Der CJ: Inhibition of
ras for cancer treatment: The search continues. Future Med Chem.
3:1787–1808. 2011.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Bamford S, Dawson E, Forbes S, Clements J,
Pettett R, Dogan A, Flanagan A, Teague J, Futreal PA, Stratton MR
and Wooster R: The COSMIC (Catalogue of Somatic Mutations in
Cancer) database and website. Br J Cancer. 91:355–358.
2004.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Tan C and Du X: KRAS mutation testing in
metastatic colorectal cancer. World J Gastroenterol. 18:5171–5180.
2012.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Prior IA, Lewis PD and Mattos C: A
comprehensive survey of ras mutations in cancer. Cancer Res.
72:2457–2467. 2012.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Jančík S, Drábek J, Radzioch D and Hajdúch
M: Clinical relevance of KRAS in human cancers. J Biomed
Biotechmol. 2010(150960)2010.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Gideon P, John J, Frech M, Lautwein A,
Clark R, Scheffler JE and Wittinghofer A: Mutational and kinetic
analyses of the GTPase-activating protein (GAP)-p21 interaction:
The C-terminal domain of GAP is not sufficient for full activity.
Mol Cell Biol. 12:2050–2056. 1992.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Kinzler K and Vogelstein B: The genetic
basis of cancer. In: Cancer Gene Therapy. Curiel DT and Douglas JT
(eds). Humana Press, Totowa, pp9-18, 2002.
|
|
15
|
Lee S, Brophy VH, Cao J, Velez M, Hoeppner
C, Soviero S and Lawrence HJ: Analytical performance of a PCR assay
for the detection of KRAS mutations (codons 12/13 and 61) in
formalin-fixed paraffin-embedded tissue samples of colorectal
carcinoma. Virchows Arch. 460:141–149. 2012.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Bader T and Ismail A: Higher prevalence of
KRAS mutations in colorectal cancer in Saudi Arabia: Propensity for
lung metastasis. Alexandria J Med. 50:203–209. 2014.
|
|
17
|
Andreyev HJ, Norman AR, Clarke PA,
Cunningham D and Oates J: Kirsten ras mutations in patients with
colorectal cancer: The multicenter RASCAL study. J Nat Cancer Inst.
90:675–684. 1998.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Zekri J, Rizvi A, Al-Maghrabi J and Bin
Sadiq B: K-Ras in colorectal cancer tumors from Saudi patients:
Frequency, clinicopathological association and clinical outcome.
Open Colorectal Cancer J. 5:22–27. 2012.
|
|
19
|
Abubaker J, Bavi P, Al-Haqawi W, Sultana
M, Al-Harbi S, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S,
Al-Daye F, et al: Prognostic significance of alterations in KRAS
isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma. J
Pathol. 219:435–445. 2009.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Gorukmez O, Yakut T, Gorukmez O, Sag SO,
Karkucak M and Kanat O: Distribution of KRAS and BRAF mutations in
metastatic colorectal cancers in Turkish patients. Asian Pac J
Cancer Prev. 17:1175–1179. 2016.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Smith G, Carey FA, Beattie J, Wilkie MJ,
Lightfoot TJ, Coxhead J, Garner RC, Steele RJ and Wolf C: Mutations
in APC, Kirsten-ras, and p53-alternative genetic pathways to
colorectal cancer. Proc Natl Acad Sci. 99:9433–9438.
2002.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Aissi S, Buisine M, Zerimech F, Kourda N,
Moussa A, Manai M and Porchet N: KRAS mutations in colorectal
cancer from Tunisia: Relationships with clinicopathological
variables and data on TP53 mutations and microsatellite
instability. Mol Biol Rep. 40:6107–6112. 2013.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Edkins S, O'Meara S, Parker A, Stevens C,
Reis M, Jones S, Greenman C, Davies H, Dalgliesh G, Forbes S,
Hunter C, et al: Recurrent KRAS codon 146 mutations in human
colorectal cancer. Cancer Biol Ther. 5:928–932. 2006.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Licar A, Cerkovnik P, Ocvirk J and
Novakovic S: KRAS mutations in Slovene patients with colorectal
cancer: Frequency, distribution and correlation with the response
to treatment. Int J Oncol. 36:1137–1144. 2010.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Zekri J, Al-Shehri A, Mahrous M,
Al-Rehaily S, Darwish T, Bassi S, El Taani H, Al Zahrani A,
Elsamany S, Al-Maghrabi J and Sadiq BB: Mutations in codons 12 and
13 of K-ras exon 2 in colorectal tumors of Saudi Arabian patients:
Frequency, clinicopathological associations, and clinical outcomes.
Genet Mol Res. 16(4238)2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Beg S, Siraj A, Prabhakaran S, Bu R,
Al-Rasheed M, Sultana M, Qadri Z, Al-Assiri M, Sairafi R, Al-Sanea
N, et al: Molecular markers and pathway analysis of colorectal
carcinoma in the Middle East. Cancer. 121:3799–3808.
2015.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Dallol A, Buhmeida A, Al-Ahwal MS,
Al-Maghrabi J, Bajouh O, Al-Khayyat S, Alam R, Abusanad A, Turki R,
Elaimi A, et al: Clinical significance of frequent somatic
mutations detected by high-throughput targeted sequencing in
archived colorectal cancer samples. J Transl Med.
14(118)2016.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Sammoud S, Khiari M, Semeh A, Amine L,
Ines C, Amira A, Lilia K, Taher K, Sabeh M and Saadia B:
Relationship between expression of ras p21 oncoprotein and mutation
status of the K-ras gene in sporadic colorectal cancer patients in
Tunisia. Applied Immunohistochem Mol Morphol. 20:146–152.
2012.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Aissi S, Buisine M, Zerimech F, Kourda N,
Moussa A, Manai M and Porchet N: Somatic molecular changes and
histopathological features of colorectal cancer in Tunisia. World J
Gastroenterol. 19:5286–5294. 2013.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Elbjeirami W and Sughayer M: KRAS
mutations and subtyping in colorectal cancer in Jordanian patients.
Oncol Lett. 4:705–710. 2012.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Gumus M, Dane F, Karabulut B, Uygun K,
Orhan B, Aydin K and Ozen R: Interim results of observational study
to determine K-ras mutation rates in patients with metastatic
colorectal cancer in Turkey. Eur J Cancer. 49 (Suppl):S571.
2013.
|
|
32
|
Elsabah M and Adel I: Immunohistochemical
assay for detection of K-ras protein expression in metastatic
colorectal cancer. J Egypt Nat Cancer Inst. 25:51–56.
2013.PubMed/NCBI View Article : Google Scholar
|
